EUVIMEDEUVIMED entdecken
Crossref

Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition

Rieneke van de Ven, Sue Ellen Verbrugge, Marjon Al, Henk Dekker, Henk M.W. Verheul, Janet L. Anderl, Elena T. Chan, Ben A.C. Dijkmans, Willem F. Lems, Rik J. Scheper, Gerrit Jansen, Tanja D. de Gruijl

Journal of Molecular and Clinical Medicine · 2018

DOI: 10.31083/j.jmcm.2018.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular and Clinical Medicine, 2018. Verfasst von Rieneke van de Ven und 11 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bortezomib (BTZ) is a potent and reversible proteasome inhibitor which has shown efficacy in the treatment of multiple myeloma. BTZ also affects NF-$\kappa$B activity, however, the same mechanisms through which it curtails malignant cell proliferation may also compromise antitumor immunity. As dendritic cells (DC) play a vital role in the elicitation and maintenance of antitumor immunity, we herein studied the long-term effects of BTZ on human DC development and function. The CD34$^{+}$ MUTZ-3 cell line, stably transduced with human telomerase reverse transcriptase (hTERT), was employed as a sustainable model to study human steady-state DC development and was grown in the presence of gradually increasing BTZ concentrations over a period of 4 months. The resultant BTZ-adapted cells were prospectively assessed for their ability to develop into mature Langerhans cells (LC). Long-term exposure to BTZ (>10 months) at a clinically relevant and apoptosis-inducing concentration (10 nM) provoked spontaneous differentiation in surviving precursors, evidenced by increased expression levels of CD14, TNF receptors and immunoproteasome subunits. Cytokine-dependent differentiation was also enhanced, resulting in increased numbers of mature DC with higher levels of co-stimulatory molecules and an increased capacity for T cell induction. Assessment of nuclear NF-$\kappa$B subunit levels provided evidence for a role of canonical RelB/p50 activation in the enhanced DC differentiation and maturation established through prolonged BTZ exposure. We conclude that long-term treatment with low dose BTZ is consistent with DC-dependent induction of antitumor immunity.

Zitieren

APA

Ven, R. V. D., Verbrugge, S. E., Al, M., Dekker, H., Verheul, H. M., Anderl, J. L., Chan, E. T., Dijkmans, B. A., Lems, W. F., Scheper, R. J., Jansen, G., & Gruijl, T. D. D. (2018). Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition. Journal of Molecular and Clinical Medicine. https://doi.org/10.31083/j.jmcm.2018.01.005

Vancouver

Ven RVD, Verbrugge SE, Al M, Dekker H, Verheul HM, Anderl JL, et al. Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition. Journal of Molecular and Clinical Medicine. 2018. doi:10.31083/j.jmcm.2018.01.005

BibTeX
@article{Ven2018,
  author = {Ven, Rieneke van de and Verbrugge, Sue Ellen and Al, Marjon and Dekker, Henk and Verheul, Henk M.W. and Anderl, Janet L. and Chan, Elena T. and Dijkmans, Ben A.C. and Lems, Willem F. and Scheper, Rik J. and Jansen, Gerrit and Gruijl, Tanja D. de},
  title = {Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition},
  journal = {Journal of Molecular and Clinical Medicine},
  year = {2018},
  doi = {10.31083/j.jmcm.2018.01.005}
}
Kostenlos starten →